Filed under: Investing
Just like the protagonist in "Fortunately, Unfortunately" Gilead Sciences is experiencing a disproportionate amount of highs and lows.
Fortunately, the big biotech released great phase 3 data out of Japan for an experimental hepatitis-c combo treatment of the approved Sovaldi and ledipasvir which saw 100% cure rates.
Unfortunately, the cost of the hep-C cure has created a intense backlash which has spread to the UK. Their health agency, NICE, said Sovaldi's $59,000 price tag, $25,000 less than we pay in the U.S., was likely still too high for the government to pay for in all but the most severe cases.
In this episode of market checkup, the Motley Fool's health care focused investing show, analysts David Williamson and Michael Douglass discuss the highs and lows of Gilead's week and the important takeaways for investors.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
The article Cost Controls vs. Curing Citizens: Fallout from the U.K. originally appeared on Fool.com.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
Read | Permalink | Email this | Linking Blogs | Comments